Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
Efficacy and Safety of Bone-protecting and Mass-dispersesing Decoction (HuGuXiaoJiTang, HGXJT) Combining With ICIs in Bone Metastatic NSCLC Patients
Guangzhou University of Traditional Chinese Medicine
82 participants
Jun 15, 2022
INTERVENTIONAL
Conditions
Summary
This is a double-blind, randomized controlled study evaluating the efficacy and safety of HGXJT in combination with ICI-based standard treatment in lung cancer patients with bone metastases. Enrolled participates will randomly receive HGXJT or placebo during the first 4-6 cycles of ICI-based standard treatment.
Eligibility
Inclusion Criteria11
- Patients with non-small cell lung cancer diagnosed by histopathology or cytopathology.
- Presence of bone metastases.
- EGFR/ALK gene wild type.
- No prior treatment with PD-1 inhibitors (combination or monotherapy)
- Those who have not received prior antitumor therapy or have not received further antitumor therapy after failure of first-line antitumor therapy.
- PS score (ECOG) ≤ 2 points
- Normal hepatic and renal function.
- Normal hepatic function: total serum bilirubin level ≤ 1.5 times of the upper limit of normal value(ULN), serum serum aspartate aminotransferase(AST) \& alanine aminotransferase(ALT) ≤ 2.5 times ULN
- Normal renal function: serum creatinine ≤ 1.5 mg/dl (133 μmol/L) and/or creatinine clearance ≥ 60 ml/min.
- Presence of at least one assessable lesion.
- Signed informed consent, patient willing to accept this regimen, able to adhere to the medication, and good compliance.
Exclusion Criteria8
- Unable to complete the baseline assessment form
- Combination of other serious illnesses, including uncontrolled active infection, severe electrolyte disturbances, and significant bleeding tendencies.
- Pregnant or lactating women.
- Combined autoimmune diseases, hematologic disorders, or long-term use of hormones or immunosuppressive drugs.
- Combination of other uncontrolled tumors.
- Combination of severe brain or mental illness that affects the patient's ability to self-report.
- Combined organ transplant history (including bone marrow autotransplantation and peripheral stem cell transplantation).
- Those who are legally incompetent and whose medical or ethical reasons affect the continuation of the research.
Interventions
PD-1 inhibitors selected by clinicians based on patients' condition
AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel 100mg/m2+carboplatin AUC=5,q3w）for Squamous cancer patients.
The particle size and color are similar to the HGXJT, and the smell and taste are close to the HGXJT, and the bacteria test is qualified
Chinese Herbal Formula,also named as HGXJT
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05378334